[Federal Register Volume 62, Number 213 (Tuesday, November 4, 1997)]
[Notices]
[Page 59735]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-29062]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on August 18, 1997, Guilford 
Pharmaceuticals, Inc., 6611 Tributary Street, Baltimore, Maryland 
21224, made application by renewal to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of cocaine 
(9041) a basic class of controlled substance listed in Schedule II.
    The firm plans to manufacture a cocaine derivative which is an 
intermediate for the production of dopascan injection. Cocaine 
derivatives are Schedule II controlled substances in the cocaine basic 
class.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, D.C. 20537, Attention: DEA Federal Register Representative 
(CCR), and must be filed no later than January 5, 1997.

    Dated: October 22, 1997.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 97-29062 Filed 11-3-97; 8:45 am]
BILLING CODE 4410-09-M